TD Asset Management Inc Sells 25,321 Shares of IDEXX Laboratories, Inc. $IDXX

TD Asset Management Inc lowered its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 7.7% in the 3rd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 304,190 shares of the company’s stock after selling 25,321 shares during the period. TD Asset Management Inc owned 0.38% of IDEXX Laboratories worth $194,344,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Counterpoint Mutual Funds LLC purchased a new stake in IDEXX Laboratories in the third quarter worth $323,000. Mufg Securities Americas Inc. lifted its position in IDEXX Laboratories by 21.1% during the third quarter. Mufg Securities Americas Inc. now owns 2,158 shares of the company’s stock valued at $1,379,000 after buying an additional 376 shares during the period. Compound Planning Inc. boosted its holdings in shares of IDEXX Laboratories by 80.2% during the 3rd quarter. Compound Planning Inc. now owns 1,186 shares of the company’s stock valued at $758,000 after buying an additional 528 shares in the last quarter. Dakota Wealth Management grew its position in shares of IDEXX Laboratories by 90.4% in the 3rd quarter. Dakota Wealth Management now owns 4,243 shares of the company’s stock worth $2,711,000 after buying an additional 2,015 shares during the period. Finally, Stonebrook Private Inc. bought a new position in shares of IDEXX Laboratories in the 3rd quarter worth about $222,000. Hedge funds and other institutional investors own 87.84% of the company’s stock.

IDEXX Laboratories Price Performance

Shares of IDXX opened at $657.38 on Thursday. IDEXX Laboratories, Inc. has a twelve month low of $356.14 and a twelve month high of $769.98. The company has a market capitalization of $52.34 billion, a P/E ratio of 50.30, a price-to-earnings-growth ratio of 3.94 and a beta of 1.67. The firm has a 50 day moving average of $674.55 and a 200 day moving average of $668.99. The company has a quick ratio of 0.90, a current ratio of 1.23 and a debt-to-equity ratio of 0.23.

IDEXX Laboratories (NASDAQ:IDXX) last issued its earnings results on Monday, February 2nd. The company reported $2.92 EPS for the quarter, missing the consensus estimate of $2.93 by ($0.01). The business had revenue of $1.09 billion for the quarter, compared to analysts’ expectations of $1.07 billion. IDEXX Laboratories had a net margin of 24.62% and a return on equity of 69.78%. The business’s revenue for the quarter was up 14.3% on a year-over-year basis. During the same quarter in the prior year, the business posted $2.53 earnings per share. IDEXX Laboratories has set its FY 2026 guidance at 14.290-14.800 EPS. As a group, equities research analysts anticipate that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current fiscal year.

Insider Activity at IDEXX Laboratories

In related news, EVP Michael G. Erickson sold 5,371 shares of IDEXX Laboratories stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $627.38, for a total value of $3,369,657.98. Following the completion of the sale, the executive vice president directly owned 12,693 shares in the company, valued at approximately $7,963,334.34. This trade represents a 29.73% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Sophie V. Vandebroek sold 1,464 shares of the business’s stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $628.62, for a total value of $920,299.68. Following the completion of the transaction, the director directly owned 648 shares of the company’s stock, valued at approximately $407,345.76. This trade represents a 69.32% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 18,180 shares of company stock valued at $11,626,996 over the last ninety days. Insiders own 0.98% of the company’s stock.

Analyst Ratings Changes

A number of research analysts recently issued reports on the stock. Leerink Partners set a $785.00 price target on shares of IDEXX Laboratories in a research report on Monday, November 3rd. BTIG Research lowered their target price on shares of IDEXX Laboratories from $830.00 to $800.00 and set a “buy” rating for the company in a report on Tuesday, February 3rd. Piper Sandler cut their price target on IDEXX Laboratories from $775.00 to $750.00 and set a “neutral” rating on the stock in a research note on Monday, February 9th. Morgan Stanley raised their price objective on IDEXX Laboratories from $765.00 to $805.00 and gave the company an “overweight” rating in a research report on Tuesday, November 4th. Finally, Barclays dropped their target price on IDEXX Laboratories from $850.00 to $800.00 and set an “overweight” rating on the stock in a report on Thursday, February 5th. Seven analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $783.33.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.